Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Favorable survival and tolerability of the GMALL protocol in adolescents and young adults with ALL: A single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

NONicola OrlovERElena RibakovskyMKMeirav Kedmi

Discussion

Loading...

Member takes

Overview

Retrospective cohort finds favorable survival in adolescents and young adults with acute lymphoblastic leukemia using GMALL protocols, suggesting effective treatment options.

Key Points

  • Overall survival at three years was 73% for patients aged 18-40 with acute lymphoblastic leukemia.
  • The morphological remission rate post induction was 92%, highlighting the efficacy of the GMALL protocol.
  • This retrospective cohort study utilized Kaplan–Meier methods to estimate survival outcomes effectively.
  • Findings support the GMALL protocol as a well-tolerated treatment for acute lymphoblastic leukemia in young adults.

Cite This Study

Orlov et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4e4https://doi.org/10.1182/blood-2025-6863
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world data of adolescents and young adults with acute lymphoblastic leukemia treated with a modified GMALL protocol in India: Treatment outcomes and challenges2025
  2. 2Overall survival in patients with acute lymphoblastic leukemia in the aya population, treated with modified pediatric chemotherapeutic schemes, a real-life study2025
  3. 3Effectiveness and prognostic impact of BMI, MRD and CNS involvement in AYA patients with Philadelphia-negative ALL treated using the AYA-15 protocol: Real-world from a tertiary center in the middle east2025
  4. 4T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults2025 · 2 citations
  5. 5Outcomes of adolescent and young adult patients with AML treated on adult versus pediatric protocols2025